When new cancer drugs are shown to be largely ineffective, exceptional cases of good outcome may pave the way for new treatments that could benefit a smaller group of patients.

In the most rigorous analysis of its kind to date, Memorial Sloan-Kettering researchers find acupuncture to be an effective therapy for several types of pain.

Internationally recognized physician-scientist José Baselga has been named Physician-in-Chief of Memorial Hospital. He joins Memorial Sloan-Kettering from Massachusetts General Hospital.

Enzalutamide, a targeted therapy co-invented by a Memorial Sloan-Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer.

Memorial Sloan-Kettering investigators have found that some testicular cancers arising early in life may result from genetic changes that have not been inherited from either parent.

New studies investigate how the use of antibiotics affects the balance of both harmful and beneficial bacteria in patients undergoing stem cell transplantation.

Memorial Sloan-Kettering surgeons have pioneered a technique that may improve quality of life for women with early-stage gynecologic cancers.